Low incidence of Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly in Tianjin, northern China

Yi Pan(Jiangsu Normal University), Kai Fu(Soochow University), Chengfeng Bi(Sichuan University), Fujin Liu(Hainan 301 Hospital), Weiyun Z. Ai(City College of San Francisco), Huaqing Wang(Tianjin People's Hospital), Wenfeng Cao(Tianjin Medical University Cancer Institute and Hospital), Bin Meng(Soochow University), Xishan Hao(Tianjin Medical University Cancer Institute and Hospital), Baocun Sun(Tianjin Medical University Cancer Institute and Hospital), Huilai Zhang(Shanxi Medical University)
Leukemia & lymphoma/Leukemia and lymphoma
July 25, 2012
10.3109/10428194.2012.715347
Cited by 24

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma
|International Journal of Oncology|2015|271